



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07K 14/47, C12N 9/12, 15/62, 15/12, C07K 16/18, A01K 67/027</b>		<b>A1</b>	(11) International Publication Number: <b>WO 99/65939</b>
			(43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: <b>PCT/US99/13659</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 18 June 1999 (18.06.99)			
(30) Priority Data: 09/099,857 18 June 1998 (18.06.98) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/099,857 (CIP) Filed on 18 June 1998 (18.06.98)			
(71) Applicant (for all designated States except US): CURAGEN CORPORATION [US/US]; 11th floor, 555 Long Wharf Drive, New Haven, CT 06511 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): NANDABALAN, Krishnan [IN/US]; 228 Village Pond Road, Guilford, CT 06437 (US). YANG, Meijia [CN/US]; 6 Catbird Lane, East Lyme, CT 06333 (US).			
(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).			

(54) Title: INTERACTION OF p27(KIP1) WITH FKBP-12

## (57) Abstract

The present invention discloses an interaction between p27(Kip1) and FKBP-12 and the formation of a p27(Kip1).FKBP-12 complex, or of the derivatives, fragments, analogs and homologs thereof, that were identified using a modified, improved yeast two hybrid assay system. Methodologies of screening these aforementioned complexes for efficacy in treating and/or preventing various diseases and disorders, particularly hyperproliferative

DEMONSTRATION OF THE  
P27(KIP1):FKBP12 INTERACTION

	P27(Kip1)	A1	B1
CDK2	+	-	-
FKBP-12	+	-	-
TRK	-	-	-
CYC-B	-	-	-
Vector	-	-	-

disorders, including, but not limited to, cancer, neurodegenerative disease, autoimmune disease, and the like, are also disclosed herein.